IMRX
NASDAQ · Biotechnology
Immuneering Corp - Class A
$4.48
+0.02 (+0.45%)
Open$4.46
Previous Close$4.46
Day High$4.52
Day Low$4.42
52W High$10.08
52W Low$3.86
Volume—
Avg Volume800.4K
Market Cap288.55M
P/E Ratio—
EPS$-1.03
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
-21.0% upside
Current
$4.48
$4.48
Target
$3.54
$3.54
$2.50
$3.54 avg
$3.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |
| Rev Growth | -6.7% | +18.5% | +10.5% |
| Debt/Equity | 0.36 | 0.44 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.99 | -0.08% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.46 | -0.92% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.37 | -1.51% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $799.26 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.45 | -2.07% | 40.0 | 32.33B |